Moringa BURST continuously reviews newly published moringa research and adds relevant human studies to the Moringa Research Library. We publish these summaries to make current moringa evidence easier to find, understand, and evaluate — including findings that challenge earlier research or do not support common moringa claims.
This article covers a randomized, double-blind, placebo-controlled human trial first published on 28 August 2026. The researchers studied Moringa oleifera leaf extract for 90 days in adults with obesity, looking not only at body composition but also blood sugar, cholesterol, gut microbiota, and metabolites.
The findings are interesting, particularly because they appeared only a few months after a 2026 meta-analysis found no significant overall effect of moringa on body weight or BMI. However, this new trial was relatively small and had substantial missing follow-up data, so it should not be interpreted as proof that moringa causes weight loss.
Study snapshot
Why this new study matters
This paper is valuable because it adds new primary human evidence rather than re-analysing older trials.
It is also unusually relevant to the current evidence picture. In May 2026, a systematic review and meta-analysis of eight randomized controlled trials reported no significant overall changes in body weight or BMI with moringa. This new trial was published three months later and therefore was not part of that evidence synthesis.
That does not mean the new trial overturns the meta-analysis. One small study cannot do that. Instead, it becomes another piece of evidence that should eventually be considered alongside the existing trials.
What the researchers did
The researchers recruited adults with what the paper describes as simple obesity, defined for the study using a BMI of at least 28 kg/m² and without other chronic illnesses.
Sixty-three eligible participants were randomly assigned to a placebo group or a moringa leaf extract group. The intervention was double-blinded, meaning the study was designed so participants and researchers would not know which treatment each participant was receiving during the trial.
Participants in the moringa group consumed two intervention packs each day, one before breakfast and one before dinner. Each 8 g pack contained 2 g of moringa leaf extract, 2 g of peach powder, and 4 g of isomaltose, giving a total of 4 g of moringa leaf extract per day. The placebo packs contained peach powder and isomaltose without moringa.
Both groups also received dietary and lifestyle guidance from dietitians during the three-month study. This is important when interpreting changes in body weight because moringa was not the only lifestyle-related intervention taking place.
What happened to BMI and body composition?
Both groups lost weight during the study.
After two months, BMI had fallen by 1.5 kg/m² from baseline in the placebo group and by 2.16 kg/m² in the moringa group. The decrease was significantly greater in the moringa group at that point.
However, the picture became less clear by the end of the study. The researchers reported that although weight loss had been more pronounced in the moringa group, particularly during the second month, the difference in weight loss between groups was no longer statistically significant by the third month.
The authors also reported better preservation of fat-free mass, muscle mass, and basal metabolic rate at some measurements, but the early advantage in fat-free body weight was not sustained across the full three months.
This distinction matters. Describing the trial simply as proof that moringa caused weight loss would leave out an important part of the result.
What happened to HbA1c and blood lipids?
After three months, HbA1c — a marker reflecting average blood glucose over the preceding months — decreased by 0.10 percentage points in the placebo group and by 0.31 percentage points in the moringa group. The between-group difference was statistically significant.
Fasting glucose moved in a favourable direction in the moringa group but the between-group difference was not statistically significant.
HDL cholesterol also differed significantly between groups. HDL-C decreased by 0.04 mmol/L in the placebo group and increased by 0.05 mmol/L in the moringa group. The researchers did not find significant differences in the other lipid measurements.
These results are interesting metabolic signals, but a small 90-day study does not establish that moringa prevents or treats diabetes, high cholesterol, or cardiovascular disease.
What did the gut microbiota analysis find?
The study also analysed stool samples to investigate whether moringa was associated with changes in intestinal microorganisms.
The researchers did not find a significant overall difference in microbial diversity or overall community structure between the groups. However, they did identify differences in the abundance of nine individual bacterial taxa.
Some taxa, including Lachnospiraceae and Muribaculaceae, were more abundant in the moringa group, while Erysipelotrichaceae was more abundant in the control group.
The study also found significantly lower faecal acetic acid in the moringa group, while the other measured short-chain fatty acids did not differ significantly between groups.
These findings should be treated as exploratory. Gut microbiome research is complex, and a change in the abundance of particular bacteria does not automatically translate into a proven health benefit.
What did the metabolomics show?
Untargeted metabolomic analysis identified numerous metabolites that differed between the groups, with differences concentrated in several pathways related to lipid and energy metabolism.
The researchers also reported correlations between some metabolites, gut bacteria, BMI, HbA1c, HDL cholesterol, and muscle mass.
Correlations can help researchers develop hypotheses about how an intervention might work, but they do not prove that one biological change caused another. These findings are better viewed as leads for future research than as established mechanisms.
The participant numbers need careful attention
This is one of the most important limitations of the study.
Sixty-five volunteers were initially recruited, two were excluded, and 63 were randomized: 29 to placebo and 34 to moringa. However, the paper reports complete data for only 35 participants, and the number of participants available for individual analyses varied considerably.
For example, the body-composition analyses included 43 participants at month one, 33 at month two, and 33 at month three. HbA1c and HDL-C analyses used 34 participants, while some gut-microbiota analyses used only 24.
The researchers explain that participants missed measurements for reasons including travel, work commitments, distance, and illness. They also noted intermittent adherence among some participants.
Missing data and inconsistent adherence make a small trial harder to interpret because the participants who completed particular measurements may not fully represent everyone who was originally randomized.
How does this compare with the July 2026 weight evidence?
This is where the study becomes particularly useful.
A 2026 systematic review and meta-analysis previously summarized eight randomized trials and found no significant pooled effect of moringa on body weight or BMI. Our July Research Library summary therefore concluded that the available randomized evidence did not support presenting moringa as a proven weight-loss intervention.
This new August trial adds a more recent positive BMI signal at month two, but it does not justify reversing that conclusion. The trial is small, the weight difference was not significant by month three, and there was substantial missing follow-up data.
The evidence has therefore changed slightly, but not decisively. The responsible position remains that moringa is being actively studied in relation to body composition and metabolic health, while human evidence is not yet strong or consistent enough to establish it as a weight-loss treatment.
What this study does not prove
This study does not prove that moringa causes reliable or sustained weight loss.
It does not prove that moringa is a fat burner or obesity treatment.
It does not prove that moringa prevents or treats diabetes, high cholesterol, or other metabolic diseases.
It does not establish that the observed microbiome changes caused the changes in BMI, HbA1c, or HDL cholesterol.
It does not show that every moringa powder, capsule, or extract will produce the same results.
It does not establish an optimal daily moringa dose.
It does not test BURST Moringa Powder or BURST Moringa Capsules specifically.
How this fits into the wider moringa evidence picture
This study is a good example of why scientific evidence should be treated as something that develops over time rather than as a collection of isolated headlines.
Earlier pooled randomized evidence did not show a significant overall effect on body weight or BMI. This newer trial adds a positive BMI result at one time point, alongside interesting findings for HbA1c, HDL cholesterol, body composition, gut microbiota, and metabolomics.
Those results deserve to be documented. They also deserve to be kept in proportion.
Larger randomized trials with better participant retention, consistent adherence, clearly defined primary outcomes, and independent replication would provide much stronger evidence about whether these findings are reproducible.
Related research topics
- Moringa human clinical trials
- Moringa and body weight
- Moringa and BMI
- Moringa and HbA1c
- Moringa and HDL cholesterol
- Moringa and gut microbiota
- Moringa metabolomics research
- Randomized controlled trials
- Cardiometabolic health research
- Study limitations and evidence quality
Related reading
- Moringa Research Library
- Moringa, Body Weight, and Blood Pressure: A 2026 Review of Randomized Trials
- Meta-Analysis of Moringa Supplementation and Cardiometabolic Outcomes
- 2026 Human Trial: Moringa Improved Glycemic and Inflammatory Markers in Adults with Metabolic Syndrome
Study source
Zhou X, He D, Xiong J, et al. Impacts of M. oleifera Leaf Extract on Weight Loss, the Metabolomic Profile, and the Intestinal Microbiota in Individuals With Simple Obesity. Food Science & Nutrition. 2026;14(9):e72292.
DOI: 10.1002/fsn3.72292
Educational note
This summary is for educational purposes only. It is not medical advice and should not be used to diagnose, treat, cure, or prevent obesity, diabetes, cardiovascular disease, or any other medical condition. If you are managing your weight or blood sugar, take medication, are pregnant or breastfeeding, or have a medical condition, speak to a qualified healthcare professional before using moringa.
